Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 2693 • ACR Convergence 2025
CAR T-cell Therapy in SLE: A Systematic Review
Alberto Nordmann-Gomes¹, Leila Khalili², Wei Tang³, Laura Geraldino-Pardilla⁴, Yevgeniya Gartshteyn⁵, Robert Clancy⁴, Stephen Suh⁶, Maya Souvignier⁶, Michel Sadelain⁶ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Westchester Medical Center, Valhalla, NY, ⁴Columbia University, New York, NY, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶Columbia University Irving Medical Center, New York City, NY
Background/Purpose: CAR T-cell therapy is poised to revolutionize the treatment of systemic lupus erythematosus (SLE). Recently, several authors have reported their experience using CAR T-cell…
Abstract Number: 2600 • ACR Convergence 2025
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
Nicholas Sugiarto¹, Michelle Curtis², Siddarth Gurajala², Thomas Eisenhaure³, Qian Xiao⁴, Joseph Mears⁵, Arnon Arazi⁶, Paul Hoover⁷, Celine Berthier⁸, Saori Sakaue⁹, Andrea Fava¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Brad Rovin¹³, Jennifer Barnas¹⁴, Maria Dall'Era¹⁵, Chaim Putterman¹⁶, Diane Kamen¹⁷, Maureen McMahon¹⁸, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Jeffrey Hodgin²¹, Fernanda Payan Schober²², Mariko Ishimori²³, Michael Weisman²³, William Apruzzese²⁴, Joel Guthridge²⁵, Michael Brenner²⁶, Jennifer Anolik²⁷, David Wofsy²⁸, Judith James²⁵, Deepak Rao⁷, Anne Davidson²⁹, Michelle Petri³⁰, Jill Buyon³¹, Nir Hacohen³², Betty Diamond³³ and Soumya Raychaudhuri⁷, ¹Harvard Medical School, Brookline, MA, ²Harvard Medical School, Boston, ³Broad Institute, Cambridge, MA, ⁴Harvard Medical School, Boston, MA, ⁵Michigan University, Ann Arbor, MI, ⁶Feinstein Institutes for Medical Research, Acton, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Washington, Yokohama, Japan, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Cincinnati Children's Hospital, Cincinnati, OH, ¹²UC Health, Cincinnati, ¹³The Ohio State University, Columbus, OH, ¹⁴University of Rochester, Rochester, NY, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶Albert Einstein College of Medicine, Safed, Israel, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁹UCLA, Sherman Oaks, CA, ²⁰UC San Diego, La Jolla, CA, ²¹University of Michigan, Ann Arbor, ²²TTUHSC, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴Pfizer, Boston, ²⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁷University of Rochester Medical Center, Rochester, NY, ²⁸University of California San Francisco, SF, CA, ²⁹Feinstein Institutes for Medical Research, Manhasset, NY, ³⁰Johns Hopkins University School of Medicine, Timonium, MD, ³¹NYU Grossman School of Medicine, New York, NY, ³²Broad Institute of MIT Harvard, Cambridge, MA, ³³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2448 • ACR Convergence 2025
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Haiting Wang¹, Liling Zhao², Shuang Ye³ and Shaoying Yang², ¹Renji Hospital, Rockville, MD, ²Renji hospital, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
Abstract Number: 2431 • ACR Convergence 2025
Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
Sungwon Ko¹, Young-Eun Kim¹, Soyoon Yoon², Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee³, Bin Yoo¹, Dong Yun Lee⁴ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea, ⁴Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a noninvasive imaging modality widely used to assess inflammatory activity in various autoimmune and hematologic…
Abstract Number: 2411 • ACR Convergence 2025
The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
Luca Mazzoleni¹, Francesca Crisafulli², Md Yuzaiful Md Yusof³, Aamir Aslam⁴, Andrew Barr⁵, Lesley-Anne Bissell⁶, Shouvik Dass⁵, Jack E Arnold⁷, Ed Vital⁸, Franco Franceschini⁹ and Porntip Intapiboon¹⁰, ¹University of Brescia, Brescia, Italy, ²ASST Spedali Civili and University of Brescia, Brescia, Italy, ³University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds teaching hospitals- NHS trust, Leeds, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁷Leeds Institute of Rheumatic & Musculoskeletal Medicine, Leeds, United Kingdom, ⁸University of Leeds, Leeds, England, United Kingdom, ⁹University of Brescia, Brescia, Brescia, Italy, ¹⁰Prince Of Songkla universitiy, Tambon Kohong, Thailand
Background/Purpose: To assess the 2012 SLICC and 2019 EULAR/ACR classification criteria performance as diagnostic criteria in two cohorts of ANA-positive patients clinically suspected of having…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 2201 • ACR Convergence 2025
Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Akhil Sood¹, Leanna Wise², Sadaf Sediqi¹, Alyssa Howren¹, Amanda Moyer¹, Ellie Diamond¹, Yashaar Chaichian³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²LAGMC/Keck Medicine of USC, Los Angeles, ³Stanford University, Stanford, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: The American College of Rheumatology has established guidelines for managing reproductive health in patients with rheumatic diseases. We assessed contraception use and counseling of…
Abstract Number: 1918 • ACR Convergence 2025
Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
Heather Gold¹, Yi Li¹, Isabella Giunta¹, Jill Buyon¹, Peter Izmirly², Mala Masson³, Amit Saxena¹, H Michael Belmont⁴, Chung-E Tseng⁵ and Rebecca Anthopolos¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Health, New York, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Flushing, NY
Background/Purpose: Physical activity can mitigate cardiovascular disease and depression risk and improve fatigue, physical function, and quality of life in patients with SLE. To facilitate…
Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1817 • ACR Convergence 2025
Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
Heather Cross¹, Hannah Peckham¹, Gary Butler², Elizabeth Rosser³, Elizabeth C Jury¹, George Robinson¹ and Coziana Ciurtin¹, ¹University College London, London, United Kingdom, ²University College London Hospital NHS Trust, London, England, United Kingdom, ³University College London, London, England, United Kingdom
Background/Purpose: Sex determinants may play a role in the immunological sexual dimorphism of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the impact…
Abstract Number: 1717 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Anubhav Singh⁴, Cristina Reategui-Sokolova⁵, Claudia Elera-Fitzcarrald⁵, Samira Garcia-Hirsh⁶, Cesar Pastor-Asurza⁷, Zoila Rodriguez-Bellido⁸, Risto Perich-Campos⁹, Graciela Alarcón¹⁰ and Manuel Ugarte-Gil¹¹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Baptist hospital of southeast Texas, Beaumont, TX, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁸Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁹Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ¹⁰The University of Alabama at Birmingham, Oakland, CA, ¹¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Frailty has been shown to predict damage accrual in patients with SLE, including those from Latin America. However, the impact of frailty on mortality…
Abstract Number: 1634 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus With Incident Heart Failure Requiring Hospitalization
Chun-Yu Lin, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan (Republic of China)
Background/Purpose: Cardiovascular complications are increasingly recognized as a significant cause of late mortality in patients with systemic lupus erythematosus (SLE). Although coronary heart disease risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].